August 28, 2015
Persistent leukemia-associated mutations in at least 5% of bone marrow cells in day 30 remission samples appeared to significantly increase the risk for relapse and mortality in patients with acute myeloid leukemia, according to the results of a comprehensive genomic analysis.
“Most patients with AML fall into a gray area when it comes to being able to predict their risk of relapse,” Timothy J. Ley, MD, professor of oncology and chief of the section of stem cell biology at Washington University School of Medicine in St. Louis, said in a press release. “About 80% of AML patients go into remission with chemotherapy, but most of them eventually will relapse. Unfortunately, we still don’t have a definitive test that tells us early on which patients will relapse.”